Search results: (10000)
News With MD Eva Drbohlavová on Innovations in the Treatment of von Willebrand Disease and Improving Patients' Quality of Life
Von Willebrand Disease (vWD), as the most common congenital bleeding disorder, remains underdiagnosed. However, thanks to new insights and advances in genetic testing, both diagnosis and long-term prophylaxis of the disease are gradually improving, leading to a significant reduction in bleeding and better quality of life for patients. We discuss this in more detail with MD Eva Drbohlavová from the Department of Clinical Hematology at the Regional Hospital Liberec.
News Do Asthma Bronchiale and COPD Represent a Risk Factor for Severe COVID-19 and Death?
It is well known that patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) have a higher risk of severe course of common viral respiratory diseases. A study by Belgian authors involving several hundred individuals evaluated the risk of ICU admission and death due to COVID-19 in patients with asthma and COPD compared to patients without these conditions. The other goal was to determine whether these risks are influenced by inhalation corticosteroid therapy or not.
News Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
News Probiotic L. reuteri in combination with vitamin D3 and krill oil suppresses experimental intestinal inflammation
Previous placebo-controlled studies have shown that oral administration of a probiotic containing Lactobacillus reuteri is associated with a significant increase in plasma levels of 25-hydroxyvitamin D. According to a recent experimental work, the combination of this probiotic with vitamin D3 and krill oil leads to the suppression of intestinal mucosal inflammation.
News Can Empagliflozin Also Act Against Gout?
Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective antidiabetic agents but also exhibit cardio- and renoprotective effects. It now appears that in type 2 diabetics, they may lower serum uric acid levels and help prevent the development of gout. This was suggested by a post hoc analysis of data from the EMPA-REG OUTCOME study in the case of empagliflozin.
News Treatment of Glaucoma: Without Preservatives for Everyone?
A comprehensive report by Professor John Thygesen from the University Hospital in Copenhagen analyzes patient groups for whom preservative-free antiglaucoma medications are particularly suitable. In conclusion, he suggests that if there are no price differences, widespread treatment with preservative-free preparations is preferable.
News Impact of Sacubitril/Valsartan Treatment on Left Ventricular Reverse Remodeling
A meta-analysis evaluated the effect of sacubitril/valsartan on echocardiographic parameters (not only) in patients with HFrEF. The authors focused on both the presence and significance of changes, as well as the speed of their onset after the initiation of treatment.
News Fresh data from real clinical practice on targeted treatment of RA with etanercept: Should therapy be changed after 12 weeks due to insufficient response?
A recently published German study investigated, among other things, what percentage of patients with rheumatoid arthritis (RA) achieve remission or low disease activity after a certain period of etanercept treatment in real clinical practice.
News Somapacitan administered once weekly in the treatment of children with growth hormone deficiency – current understanding
Somapacitan is a long-acting derivative of recombinant human growth hormone approved for the treatment of children and adults with growth hormone (GH) deficiency. Dr. Reiko Horikawa from Japan's National Center for Child Health and Development in Tokyo, during the 24th Pediatric Endocrinology Days held in Brno in January 2024, showed that it is a promising therapeutic option for pediatric patients from 3 years of age, thanks to its efficacy, safety, and potential to improve therapy adherence. However, careful long-term monitoring of the safety of long-acting growth hormone (LAGH) products is still necessary.
News Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?
Administering an infusion of activated prothrombin complex concentrate (aPCC) at the standardized rate of 2 U/kg/min can be time-consuming, especially when repeated applications are needed. The authors of the recently published multicenter study cited below focused on the safety and tolerability of reducing the infusion volume by 50% and increasing the infusion rate to 4 and 10 U/kg/min.
News Efficacy of Brigatinib in Patients with Metastatic NSCLC − Real-World Clinical Data
The journal Lung Cancer published the results of a retrospective analysis of the efficacy of brigatinib in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who participated in a European early access treatment program.
News HAE in the Otolaryngologist's Office: How to Handle a Laryngeal Attack?
Hereditary angioedema (HAE) can be encountered in emergency rooms and specialist offices. Patients with this rare disorder are often misdiagnosed with a more common condition, and they may learn their correct diagnosis only after many years. This is because HAE manifests with a combination of symptoms that are typical of various other diseases. What should pediatricians, otorhinolaryngologists, and gastroenterologists be aware of? Providing better understanding of HAE symptoms from different specializations' perspectives and emphasizing the importance of interdisciplinary collaboration for accurate diagnosis and patient care was the focus of a professional webinar we have summarized for you.
News Efficacy and Safety of Fixed Combination of Olopatadine and Mometasone in Nasal Spray for Treatment of Seasonal Allergic Rhinitis
Patients with allergic rhinitis require medications with rapid onset and long duration of action. The combination of intranasal antihistamines and corticosteroids has proven effective in the past. The efficacy and safety of a fixed combination of olopatadine and mometasone in a nasal spray (GSP301) was evaluated in the study presented below by a team of American authors.
News How to Set Individual Treatment Goals for Type 2 Diabetes?
Treatment goals for type 2 diabetes should always be set individually. In practice, this mainly involves an indicator of the success of long-term compensation – glycated hemoglobin (HbA1c). Recommendations for the diagnosis and treatment of diabetes for general practitioners from 2020 list different target HbA1c values according to the risk of hypoglycemia and other parameters. They also recall different target values for fit, frail, and dependent seniors.
News Incidence of CV Events, Malignancies, and Venous Thromboembolism in Patients with RA According to Baseline CV Risk and Administered Treatment
An international team of experts evaluated the impact of cardiovascular (CV) risk on the incidence and risk of major CV events, malignancies, and venous thromboembolism (VTE) in patients with rheumatoid arthritis (RA) treated with tofacitinib compared to tumor necrosis factor (TNF) inhibitors, depending on the level of CV risk at the initiation of this therapy. The authors used data from the ORAL Surveillance study.
News Relationship Between Mortality and Use of Statins or RAAS Inhibitors After Aortic Valve Replacement
The impact of prescribed medication after transcatheter aortic valve replacement (TAVR) has not been precisely assessed to date. A recently published retrospective analysis of clinical practice data from patients who underwent TAVR aimed to assess the potential benefit of using statins and renin-angiotensin-aldosterone system (RAAS) inhibitors.
News Prediction of DM2 and CVD Development Risk Based on Lipidomic Risk Determination
The incidence of type 2 diabetes mellitus (DM2) and cardiovascular diseases (CVD) is strongly influenced by lifestyle and diet. Hypertension, hypercholesterolemia, and elevated blood glucose are often detectable before the full development of disease symptoms. Similarly, changes in the representation of other less noticeable markers—plasma lipids—can also be detected.
News Study COPDGene Redefines Diagnostic Criteria of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease ranks among the top causes of morbidity and mortality worldwide. Current diagnostic criteria for the disease are based exclusively on spirometric examination. Increasing evidence, however, suggests that a significant number of patients show signs of chronic obstructive pulmonary disease without pathological findings on spirometry. The analysis of the COPDGene study thus proposes expanding the diagnostic criteria to include additional parameters.
News Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer
A pooled analysis of 25 studies with patients in the first line of treatment for metastatic colorectal cancer (mCRC) evaluated the prognostic and predictive significance of body mass index (BMI). Until its publication in 2015, only the adverse impact of low and high BMI on outcomes in patients with early stages of colorectal cancer was known.
News Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC
A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors – brigatinib, followed by lorlatinib – in real-world clinical practice.
News Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress, was to assess the efficacy and safety of therapy in patients with ALK-positive NSCLC naïve to previous ALKi therapy.
News How Does Erdosteine Perform in Combination with Antibiotics?
Erdosteine is an oral mucoactive drug that reduces mucus viscosity by degrading disulfide bonds in the mucin polymer. It achieves this effect through a free thiol group in its main active metabolite, N-thiodiglycolyl-homocysteine. In addition to its mucolytic action, erdosteine exhibits antioxidant and anti-inflammatory effects and reduces bacterial adhesion, thereby enhancing the effectiveness of certain antibiotics. We provide a summary of study results demonstrating its effect on enhancing the efficacy of drugs administered in the treatment of respiratory diseases.
News Therapy with Cyclosporine in the Context of the Coronavirus Pandemic
The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises concerns about possible risks associated with immunosuppressive treatment of autoimmune diseases. Specifically, does the use of cyclosporine increase the risk of infection, or does it act protectively?
News CASE STUDY: Rocker who can enjoy life again thanks to DM2 compensation p.o. semaglutide and better lifestyle
Diabetologist MUDr. Lucie Radovnická from Masaryk Hospital in Ústí nad Labem illustrates the case of her patient − a sympathetic rocker who enjoys life including concerts, beer, and good food − demonstrating how modern antidiabetic treatment with oral semaglutide in combination with thorough lifestyle re-education can achieve very good diabetes compensation and overall health improvement. One of the many benefits of this modality was the possibility to discontinue sulfonylurea derivative medication, which previously caused severe hypoglycemia.